credit suisse downgrades sun pharma to ‘neutral’ vs outperform
Published 7 years ago • 65 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
6:13
disappointed investors are the 'biggest risk' to 2025: strategist
-
4:07
dow and s&p 500 notch record closes
-
4:27
expect rbnz to 'slow down' pace of monetary easing in 2025: hsbc
-
1:46
sun pharma to acquire u.s.-based concert pharmaceuticals for $576 million | bazar corporate radar
-
5:56
dr. scott gottlieb on rfk: he will cost lives in this country if he follows through on intentions
-
5:04
the consumer looks well with some pockets of weakness, says solus' dan greenhaus
-
5:40
expect sun pharma to report a strong growth led by the speciality segment: centrum | cnbc tv18
-
6:19
analyst lays out top retail picks amid brands' revamp
-
1:25
sun pharma q1fy25: net profit, ebitda, margin beat est; us formulation sales at $466 m | cnbc tv18
-
2:10
looking at the technicals on volatility
-
3:30
tesla is the most undervalued ai name in the market, could hit $2 trillion in market cap: dan ives
-
4:24
s&p '493' will do increasingly well, says yardeni research president
-
5:49
3 buys and a bail: walmart, apple, tesla & cheniere energy
-
4:11
closing bell: nifty above 24,100; sensex settles 759 points higher; airtel gains 4%, sun pharma 3%
-
1:39
claris life slips in trade
-
4:38
where to invest in glp-1 stocks
-
2:20
'clear winner:' analyst names stocks to play the ev sector
-
4:34
3-stock lunch: microsoft, peloton & disney
-
6:44
global guru speak: credit suisse
-
3:22
trade tracker: sarat sethi buys more workday
-
1:19
french bond market pain could spur leaders on, strategist says
-
8:57
3 factors that could drive stocks higher this december: strategist